Literature DB >> 33664407

Effect of captopril on post-infarction remodelling visualized by light sheet microscopy and echocardiography.

Urmas Roostalu1, Louise Thisted2, Jacob Lercke Skytte2, Casper Gravesen Salinas2, Philip Juhl Pedersen2, Jacob Hecksher-Sørensen2, Bidda Rolin2,3, Henrik H Hansen2, James G MacKrell4, Robert M Christie4, Niels Vrang2, Jacob Jelsing2, Nora Elisabeth Zois2.   

Abstract

Angiotensin converting enzyme inhibitors, among them captopril, improve survival following myocardial infarction (MI). The mechanisms of captopril action remain inadequately understood due to its diverse effects on multiple signalling pathways at different time periods following MI. Here we aimed to establish the role of captopril in late-stage post-MI remodelling. Left anterior descending artery (LAD) ligation or sham surgery was carried out in male C57BL/6J mice. Seven days post-surgery LAD ligated mice were allocated to daily vehicle or captopril treatment continued over four weeks. To provide comprehensive characterization of the changes in mouse heart following MI a 3D light sheet imaging method was established together with automated image analysis workflow. The combination of echocardiography and light sheet imaging enabled to assess cardiac function and the underlying morphological changes. We show that delayed captopril treatment does not affect infarct size but prevents left ventricle dilation and hypertrophy, resulting in improved ejection fraction. Quantification of lectin perfused blood vessels showed improved vascular density in the infarct border zone in captopril treated mice in comparison to vehicle dosed control mice. These results validate the applicability of combined echocardiographic and light sheet assessment of drug mode of action in preclinical cardiovascular research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33664407      PMCID: PMC7933438          DOI: 10.1038/s41598-021-84812-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  64 in total

1.  Early captopril prevents myocardial infarction-induced hypertrophy but not angiogenesis.

Authors:  E A Kalkman; P van Haren; P R Saxena; R G Schoemaker
Journal:  Eur J Pharmacol       Date:  1999-03-26       Impact factor: 4.432

2.  Geometric assessment of regional left ventricular remodeling by three-dimensional echocardiographic shape analysis correlates with left ventricular function.

Authors:  Ivan S Salgo; Wendy Tsang; William Ackerman; Homaa Ahmad; Sonal Chandra; Michael Cardinale; Roberto M Lang
Journal:  J Am Soc Echocardiogr       Date:  2011-10-14       Impact factor: 5.251

3.  Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.

Authors:  Scott D Solomon; Hicham Skali; Nagesh S Anavekar; Mikhail Bourgoun; Stale Barvik; Jalal K Ghali; J Wayne Warnica; Margarita Khrakovskaya; J Malcolm O Arnold; Yuri Schwartz; Eric J Velazquez; Robert M Califf; John V McMurray; Marc A Pfeffer
Journal:  Circulation       Date:  2005-06-20       Impact factor: 29.690

Review 4.  Targeting angiogenesis to restore the microcirculation after reperfused MI.

Authors:  Anja M van der Laan; Jan J Piek; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2009-06-16       Impact factor: 32.419

5.  A comparison of intervention with losartan or captopril in acute myocardial infarction.

Authors:  J Spinar; J Vitovec; L Spinarova; L Pluhacek; B Fischerova; J Toman
Journal:  Eur J Heart Fail       Date:  2000-03       Impact factor: 15.534

6.  Apical conicity ratio: a new index on left ventricular apical geometry after myocardial infarction.

Authors:  Hongguang Fan; Zhe Zheng; Wei Feng; Yan Zhang; Lixin Jin; Peng Li; Shengshou Hu
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-09       Impact factor: 5.209

7.  Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation.

Authors:  S J Rials; Y Wu; X Xu; R A Filart; R A Marinchak; P R Kowey
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

8.  Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.

Authors:  M Yoshiyama; Y Nakamura; T Omura; Y Izumi; R Matsumoto; S Oda; K Takeuchi; S Kim; H Iwao; J Yoshikawa
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

9.  Displacement analysis of myocardial mechanical deformation (DIAMOND) reveals segmental susceptibility to doxorubicin-induced injury and regeneration.

Authors:  Junjie Chen; Yichen Ding; Michael Chen; Jonathan Gau; Nelson Jen; Chadi Nahal; Sally Tu; Cynthia Chen; Steve Zhou; Chih-Chiang Chang; Jintian Lyu; Xiaolei Xu; Tzung K Hsiai; René R Sevag Packard
Journal:  JCI Insight       Date:  2019-04-18

10.  Upregulation of cardiac insulin-like growth factor-I receptor by ACE inhibition after myocardial infarction: potential role in remodeling.

Authors:  Rachael G Dean; Leon A Bach; Louise M Burrell
Journal:  J Histochem Cytochem       Date:  2003-06       Impact factor: 2.479

View more
  1 in total

1.  Dach1 Extends Artery Networks and Protects Against Cardiac Injury.

Authors:  Brian Raftrey; Ian Williams; Pamela E Rios Coronado; Xiaochen Fan; Andrew H Chang; Mingming Zhao; Robert Roth; Emily Trimm; Raquel Racelis; Gaetano D'Amato; Ragini Phansalkar; Alana Nguyen; Timothy Chai; Karen M Gonzalez; Yue Zhang; Lay Teng Ang; Kyle M Loh; Daniel Bernstein; Kristy Red-Horse
Journal:  Circ Res       Date:  2021-08-12       Impact factor: 23.213

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.